What is the 13F Pro Quality Score for GANX?

13F Pro ranks Gain Therapeutics, Inc. (GANX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GANX's current score at https://13fpro.ai/research/GANX (free sign-up required for the full ranking).

Where does 13F Pro source GANX data?

All Gain Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Gain Therapeutics, Inc. files with the SEC under CIK 1819411. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GANX in?

Gain Therapeutics, Inc. (GANX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GANX research updated on 13F Pro?

GANX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Gain Therapeutics, Inc.(GANX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1819411 GANX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.2M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

GANX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Gain Therapeutics, Inc. (GANX), a Healthcare sector company. GANX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.2m in revenue. Based on the latest XBRL financial filings (Q1 2026), Gain Therapeutics, Inc. reports net income of $-5.6M, free cash flow of $-4.7M. Top institutional holders of GANX by reported 13-F value include MARSHALL WACE, LLP, Potomac Capital Management,, JONES FINANCIAL COMPANIES LLLP, based on the most recent SEC filings. GANX trades on the Nasdaq exchange and files with the SEC under CIK 1819411. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GANX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Gain Therapeutics, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-5.6M

Free Cash Flow

Q1 2026

$-4.7M

D/E Ratio

Q1 2026

0.03

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY22 $140.1KFY23 $55.2KFY24 —FY25 —

Net Income

+1.2% YoY

$-20.2MFY 2025

FY22 $-17.6MFY23 $-22.3MFY24 $-20.4MFY25 $-20.2M

Operating Income

+8.1% YoY

$-18.7MFY 2025

FY22 $-17.8MFY23 $-22.3MFY24 $-20.4MFY25 $-18.7M

EPS (Diluted)

+31.5% YoY

$-0.61FY 2025

FY22 $-1.48FY23 $-1.71FY24 $-0.89FY25 $-0.61

Total Assets

+88.2% YoY

$22.8MFY 2025

FY22 $24.1MFY23 $18.6MFY24 $12.1MFY25 $22.8M

Total Debt

-8.5% YoY

$501.8KFY 2025

FY22 $711.5KFY23 $686.6KFY24 $548.7KFY25 $501.8K

Op. Cash Flow

+2.2% YoY

$-18.5MFY 2025

FY22 $-14.7MFY23 $-18.9MFY24 $-18.9MFY25 $-18.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	—	$55.2K -60.6%	$140.1K -15.1%	$165.0K +471.3%	$28.9K
Net Income	$-20.2M +1.2%	$-20.4M +8.3%	$-22.3M -26.6%	$-17.6M -26.6%	$-13.9M -288.3%	$-3.6M
Operating Income	$-18.7M +8.1%	$-20.4M +8.5%	$-22.3M -25.2%	$-17.8M -28.6%	$-13.8M -297.4%	$-3.5M
EPS (Diluted)	$-0.61 +31.5%	$-0.89 +48.0%	$-1.71 -15.5%	$-1.48 -8.0%	$-1.37 -17.0%	$-1.17
Total Assets	$22.8M +88.2%	$12.1M -34.9%	$18.6M -22.8%	$24.1M -38.2%	$39.0M +305.9%	$9.6M
Total Debt	$501.8K -8.5%	$548.7K -20.1%	$686.6K -3.5%	$711.5K -10.8%	$798.1K +8.1%	$738.3K
Operating Cash Flow	$-18.5M +2.2%	$-18.9M -0.0%	$-18.9M -28.4%	$-14.7M -18.8%	$-12.4M -281.6%	$-3.2M

AI Insight: GANX Financial Trends

Pre-revenue biotech burning $5M quarterly with equity halved since mid-2025; debt eliminated but cash runway increasingly constrained.

• Operating cash burn stabilized at $5M/quarter in Q3 2025–Q1 2026, down from $6M in Q2 2024.

• Shareholder equity collapsed from $12M (Q2 2024) to $4M (Q2 2025), then recovered to $14M by Q1 2026 likely via capital raise.

• Total debt reduced to $0M by Q1 2026 from $1M, but equity base remains fragile for pre-revenue stage company.

⚠ No revenue generation across 10 consecutive quarters; runway limited by $5M quarterly burn and $14M equity base.

⚠ Operating losses persisted at $4–5M/quarter in latest two quarters despite prior efficiency gains in 2024.

AI Insight: GANX Ratio Trends

Gain Therapeutics remains unprofitable with deteriorating returns; leverage surged to 0.16 in Q2 2025 before retreating.

• ROE collapsed to -160.2% in Q1 2026 from -97.8% in Q4 2025, signaling deepening net losses relative to equity base.

• Debt-to-equity peaked at 0.16 in Q2 2025, then fell to 0.03 by Q1 2026, indicating deleveraging or capital raise activity.

• ROA turned -79.5% in Q4 2025 and remains negative in TTM, reflecting ongoing operating losses on asset base.

⚠ Persistent negative ROE, ROA, and ROIC across all recent quarters—no visibility to profitability inflection.

⚠ D/E volatility (0.05 → 0.16 → 0.03) in 2025 suggests capital structure stress; monitor cash runway and funding needs.

Get alerted when GANX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Gain Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GANX

MARSHALL WACE, LLP
$3.4M1,769,788 sh
Potomac Capital Management, Inc.
$2.0M1,008,600 sh
JONES FINANCIAL COMPANIES LLLP
$1.2M631,615 sh
DME Capital Management, LP
$1.1M566,130 sh
GEODE CAPITAL MANAGEMENT, LLC
$868.5K447,342 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$836.7K431,267 sh
VANGUARD CAPITAL MANAGEMENT LLC
$775.8K399,886 sh
VANGUARD FIDUCIARY TRUST CO
$446.2K229,979 sh
BlackRock, Inc.
$436.6K225,046 sh
UBS Group AG
$427.7K220,489 sh

Fund	Value	Shares
MARSHALL WACE, LLP	$3.4M	1,769,788
Potomac Capital Management, Inc.	$2.0M	1,008,600
JONES FINANCIAL COMPANIES LLLP	$1.2M	631,615
DME Capital Management, LP	$1.1M	566,130
GEODE CAPITAL MANAGEMENT, LLC	$868.5K	447,342
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$836.7K	431,267
VANGUARD CAPITAL MANAGEMENT LLC	$775.8K	399,886
VANGUARD FIDUCIARY TRUST CO	$446.2K	229,979
BlackRock, Inc.	$436.6K	225,046
UBS Group AG	$427.7K	220,489

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GANX on your watchlist

Track score changes the day Gain Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GANX a good stock to buy?

13F Pro's AI-powered analysis of Gain Therapeutics, Inc. (GANX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GANX are available on the GANX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GANX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GANX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Gain Therapeutics, Inc.'s investment landscape.